Epstein Secrets

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

> " from June 28 and=suggests risk parity fund leverage is high and we do not think the relatio=ships have changed significantly. c=span> Today on Bloomberg: Junk Debt Keeps Climbing Desp=te Plunging Oil Prices After moving in lockstep with oil markets for much o= the last two years, high-yield bonds have gone their own way and pos=e

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

> " from June 28 and=suggests risk parity fund leverage is high and we do not think the relatio=ships have changed significantly. =/span> Today on Bloomberg: Junk Debt Keeps Climbing Desp=te Plunging Oil Prices After moving in lockstep with oil markets for much o= the last two years, high-yield bonds have gone their own way and pos=e

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

arity fund leverage is high and we do not think the relatio=ships have changed significantly. <=span> 14 EFTA_R1_01556382 EFTA02454573 Today on Bloomberg: Junk Debt Keeps Climbing Desp=te Plunging Oil Prices After moving in lockstep with oil markets for much o= the last two years, high-yield bonds have gone their own way and pos=e